Johnson & Johnson reported new long-term data showing that its investigational therapy IMAAVY (nipocalimab) delivered sustained disease control in patients with generalized myasthenia gravis (gMG) for over two years. Results from the Phase 3 Vivacity-MG3 study and its extension phase demonstrated continued improvements in symptoms, muscle strength, and quality of life, along with significant reductions in harmful IgG antibodies.

The data also indicated that patients achieving sustained minimal symptom expression experienced greater quality-of-life benefits, while many were able to reduce corticosteroid use. In parallel, Johnson & Johnson confirmed that its head-to-head EPIC study comparing IMAAVY with another FcRn blocker is now enrolling participants.

Source: PR Newswire